MedTrace Logo

Combined Antibody Screening for Celiac and Diabetes Evaluation

NCT04677699 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 64410

Last updated 2020-12-21

No results posted yet for this study

Summary

The CASCADE Study (Combined Antibody Screening for Celiac and Diabetes Evaluation) is an observational study whose primary goal is to show that population-based screening for advanced prediction of type 1 diabetes (T1D) and celiac disease (CD) is feasible to prevent diabetic ketoacidosis (DKA), improve celiac disease diagnosis, and ultimately gain public health acceptance to facilitate future prevention. It has two arms, a Birth Cohort and a Kids (cross sectional) Cohort.

Conditions

Interventions

DIAGNOSTIC_TEST

Combined Risk Score

Several factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.

Sponsors & Collaborators

  • University of Exeter

    collaborator OTHER

  • Pacific Northwest Research Institute

    lead OTHER

Principal Investigators

  • William Hagopian, MD PhD · Pacific Northwest Research Institute

Eligibility

Min Age
1 Day
Max Age
7 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-31
Primary Completion
2022-12-31
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04677699 on ClinicalTrials.gov